Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Biomarkers Market analysis
Part of: Biomarkers Market (Global)

The UK Biomarkers Market was valued at $3144.9 Million in 2025 and projected to reach to $5468.4 Million by 2030, representing a compound annual growth rate of 11.7%. The UK biomarkers market is poised for sustained expansion driven by increasing adoption of precision medicine across NHS trusts and private healthcare providers.

UK Biomarkers Market Trends and Insights

  • The UK's advanced healthcare infrastructure and strong investment in precision medicine are driving adoption of biomarker-based diagnostics and therapeutics across oncology, cardiovascular, and neurodegenerative disease segments.
  • The UK's regulatory environment and NHS integration of molecular testing are accelerating market penetration. The UK biomarkers market is expanding at a compound annual growth rate of 11.7%, outpacing global trends.
  • The UK's emphasis on early disease detection and personalized treatment pathways is fueling demand for protein, genetic, and imaging biomarkers.
  • The UK's life sciences sector and partnerships between academic institutions and commercial entities are strengthening innovation pipelines and clinical adoption rates through 2030..

Key Market Statistics

  • CAGR (2025-2030) 11.7% CAGR
  • Market Size, 2025 ~USD 3144.9 Million
  • Forecast, 2030 ~USD 5468.4 Million
  • Country UK

UK Biomarkers Market Overview

Market Valuation Growth :

The UK biomarkers market is valued at £3,144.9 million in 2025, with a projected CAGR of 11.7% through 2030, reaching £5,468.4 million. This growth significantly outpaces the global CAGR of 10.8%, positioning the UK as a high-growth market within Europe.

Advanced Healthcare Infrastructure :

The UK's NHS and private healthcare systems are increasingly integrating biomarker-based diagnostics into clinical pathways. Strong investment in precision medicine initiatives and genomic sequencing capabilities are accelerating adoption across major disease areas.

Disease Segment Leadership :

Oncology, cardiovascular, and neurodegenerative disease segments are driving UK biomarker adoption. Cancer diagnostics and companion diagnostics represent the largest opportunity, supported by NHS cancer strategies and increased early detection programs.

Regulatory & Innovation Environment :

The UK's post-Brexit regulatory framework and MHRA oversight create a streamlined pathway for biomarker test approval. Strong academic research institutions and biotech clusters in London, Cambridge, and Oxford fuel continuous innovation in biomarker discovery and validation.

UK Biomarkers Market Dynamics

  • Growing demand for early disease detection, personalized treatment selection, and improved patient outcomes will accelerate biomarker integration into routine clinical practice.
  • Investment in genomic medicine infrastructure and the UK Biobank's expanding dataset provide robust support for biomarker research and commercialization.
  • Regulatory clarity and competitive advantages in digital health integration position the UK as a leading European hub for biomarker innovation and deployment through 2030..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • The UK biomarkers market will grow from £3,144.9M (2025) to £5,468.4M (2030) at 11.7% CAGR.
      • The UK's NHS integration of molecular diagnostics is accelerating clinical adoption and reimbursement pathways.
      • The UK's precision medicine initiatives and life sciences investment are driving biomarker innovation and commercialization.
      • The UK's regulatory framework supports rapid approval and market entry for novel biomarker-based diagnostics and therapeutics.

      Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CANCER (Disease Indication)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.8% from 2025 to 2030
      Largest Segment CONSUMABLES (Offering)
      Market Size Base Year (Billions) ~USD 62.37 (2025)
      Revenue Forecast (Billions) ~USD 104.15 (2030)
      Segments Covered Offering, Type, Research Area, Technology, End User, Disease Indication, Application

      UK Biomarkers Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Offering

      • Consumables
      • Services
      • Software

      By Type

      • Assay Kits
      • Efficacy Biomarkers
      • Elisa
      • Other Consumables
      • Pharmacodynamics Biomarkers
      • Predictive Biomarkers
      • Prognostic Biomarkers
      • Protein Microarrays
      • Reagents & Chemicals
      • Safety Biomarkers
      • Surrogate Biomarkers
      • Validation Biomarkers
      • Western Blot

      By Research Area

      • Genomics
      • Metabolomics
      • Other Research Areas
      • Proteomics

      By Technology

      • Chromatography
      • Immunoassays
      • Mass Spectrometry
      • Ngs
      • Other Technologies
      • Pcr

      By End User

      • Academic & Research Institutes
      • Hospitals & Diagnostic Laboratories
      • Other End Users
      • Pharmaceutical & Biotechnologies Companies
      • Pharmaceutical & Biotechnology Companies

      By Disease Indication

      • Cancer
      • Cardiovascular Disorders
      • Immunological Disorders
      • Infectious Diseases
      • Neurological Disorders
      • Other Disease Indications

      By Application

      • Clinical Diagnostics
      • Clinical Research
      • Drug Discovery & Development
      • Other Applications
      • Personalized Medicine

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : Need UK-specific market data to develop biomarker test portfolios, navigate MHRA approval processes, and identify NHS procurement opportunities for diagnostic assays and companion diagnostics.
      • Pharmaceutical & Biotech Companies : Require detailed UK market intelligence to support precision medicine drug development, identify biomarker-driven patient populations, and plan clinical trial recruitment and commercialization strategies.
      • Healthcare Investors & Private Equity : Need comprehensive UK biomarkers market analysis to evaluate investment opportunities, assess portfolio company growth potential, and identify acquisition targets in the precision medicine space.
      • NHS Trusts & Healthcare Providers : Seek market insights to inform biomarker testing adoption decisions, budget allocation for precision medicine programs, and evaluation of diagnostic partnerships and technology vendors.
      • Market Research & Strategy Consultants : Require validated UK market data and forecasts to support client advisory work, competitive analysis, and strategic recommendations across healthcare, diagnostics, and life sciences sectors.

      Key Companies in the UK Biomarkers Market

      CompanyHQOwnershipStrongest segments
      BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics systems (chemistry, hematology, immunoassay, urinalysis, blood bank),Laboratory automation and information systems,Life science research instruments and genomic solutions,
      PRA HEALTH SCIENCESUnited StatesPrivate CompanyClinical Research (Phase I–IV services across key therapeutic areas),Data Solutions (analytics, data platforms, and related services),
      ROSETTA GENOMICSIsraelPublic CompanyRosettaGX Cancer Origin and microRNA cancer-of-origin tests,RosettaGX Reveal (indeterminate thyroid FNA),mi-LUNG and mi-KIDNEY microRNA assays,
      TRANSGENOMIC, INC.United StatesPublic CompanyOncology and pharmacogenomics lab services,Multiplexed ICE COLD-PCR reagents,Other genomic testing technologies and platforms,
      CELGENE CORPORATIONUnited StatesPrivate CompanyREVLIMID (lenalidomide),POMALYST/THALOMID (IMiD franchise ex-REVLIMID),ABRAXANE and VIDAZA/ONUREG/ISTODAX (solid tumor and myeloid oncology),
      PFIZERUnited StatesPublic CompanyInternal medicine (cardiovascular, metabolic, respiratory, gastroenterology),Vaccines,Injectables and anti-infectives (including hospital services),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology,Life Sciences,Diagnostics,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions (reagents, instruments, consumables),Analytical Instruments,Specialty Diagnostics,
      MERCK KGAAUnited StatesPublic CompanyLife Science (lab reagents, consumables, instruments, bioprocessing, CDMO/testing services),Healthcare (oncology, rare diseases, neurology/immunology, fertility, cardiovascular, metabolic/endocrine),Electronics (semiconductor materials, specialty gases, delivery equipment, display and photonics materials),
      QIAGENNetherlandsPublic CompanySample technology consumables & instruments,Molecular diagnostics assays (TB, oncology, SRH, transplant, viral load),PCR & digital PCR reagents and instruments,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITY INC.United StatesPublic CompanyDiagnostics instruments, assays, and software (prenatal, neonatal, infectious disease),Life science reagents, antibodies, and assay platforms,Detection and imaging instruments and related consumables,
      CHARLES RIVER LABORATORIESUnited StatesPublic CompanyDiscovery and Safety Assessment,Research Models and Services,Manufacturing Solutions,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyFood & Feed Testing,Environment Testing,Biopharma & Clinical Diagnostics,
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (culture media, ID/AST, blood culture, sepsis markers),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Industrial applications (food, pharma, environmental: GENE-UP, VERIFLOW, BIOBALL, TEMPO, ENDONEXT, CHEMUNEX),
      ILLUMINA, INC.United StatesPublic CompanySequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Arrays and genotyping solutions,
      JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, display and CMP materials),Plastics and Synthetic Resins (ABS, AES, AS, ASA),Life Sciences (diagnostic reagents, bioprocess materials, drug discovery support),
      GUARDANT HEALTHUnited StatesPublic CompanyGuardant360 (CDx and Liquid),Other oncology tests (Reveal, Tissue, OMNI, INFINITY),Shield colorectal cancer screening,
      LABCORPUnited StatesPublic CompanyRoutine and specialty diagnostics (core lab testing, women’s health, chronic disease, occupational and substance testing),Esoteric, genetic, and oncology testing (anatomic pathology, oncology, diagnostic genetics, pharmacogenetics),Biopharma Laboratory Services (central labs, development and trial-related testing),

      BECKMAN COULTER

      Beckman Coulter is a private American company founded in 1935 that employs 11,900 people. The company operates in the life sciences and diagnostics sector.

      PRA HEALTH SCIENCES

      PRA Health Sciences is a private American company founded in 1976 that employs 18,100 people. The company operates in the clinical research and contract research organization sector.

      ROSETTA GENOMICS

      Rosetta Genomics is a public Israeli company founded in 2000 with 86 employees. The company operates in the genomics and molecular diagnostics sector.

      TRANSGENOMIC, INC.

      Transgenomic, Inc. is a public American company founded in 1997 with 19 employees. The company operates in the genetic analysis and molecular diagnostics sector.

      CELGENE CORPORATION

      Celgene Corporation is a private American company founded in 1986 that employs 8,852 people. The company operates in the biopharmaceutical and oncology sector.

      PFIZER

      Pfizer is a public American company founded in 1950 with 1,244 employees. The company operates in the pharmaceutical sector.

      DANAHER CORPORATION

      Danaher Corporation is a public American company founded in 1969 that employs 59,000 people. The company operates in the life sciences, diagnostics, and environmental and applied solutions sectors.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public American company founded in 1956 that employs 125,000 people. The company is a leading provider of laboratory equipment, reagents, and services for research and diagnostics.

      MERCK KGAA

      Merck KGaA is a public American company founded in 1668 that employs 59,077 people. The company operates in the pharmaceutical, life sciences, and performance materials sectors.

      QIAGEN

      QIAGEN is a public Dutch company founded in 1984 that employs 5,500 people. The company provides molecular diagnostics and life sciences solutions.

      ABBOTT

      Abbott is a public American company founded in 1888 that employs 115,000 people. The company operates in the diagnostics, medical devices, nutritional products, and pharmaceuticals sectors.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public American company founded in 1999 that employs 18,000 people. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      REVVITY INC.

      Revvity Inc. is a public American company founded in 1937 that employs 11,000 people. The company operates in the life sciences and diagnostics sectors.

      CHARLES RIVER LABORATORIES

      Charles River Laboratories is a public American company founded in 1947 that employs 19,000 people. The company provides preclinical and clinical laboratory services for drug development.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public American company founded in 1952 that employs 7,450 people. The company manufactures and distributes life science research and clinical diagnostics products.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public Luxembourg company founded in 1987 that employs 65,694 people. The company provides laboratory testing services across multiple sectors including food, pharmaceuticals, and environmental testing.

      BIOMéRIEUX

      bioMérieux is a public French company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.

      ILLUMINA, INC.

      Illumina, Inc. is a public American company founded in 1998 that employs 8,625 people. The company is a leader in DNA sequencing and genetic analysis technologies.

      JSR CORPORATION

      JSR Corporation is a private Japanese company founded in 1948 that employs 7,997 people. The company operates in the materials and life sciences sectors.

      GUARDANT HEALTH

      Guardant Health is a public American company founded in 2011 that employs 2,498 people. The company provides liquid biopsy and genomic testing solutions for cancer detection and monitoring.

      LABCORP

      LabCorp is a public American company founded in 1995 that employs 66,385 people. The company is a leading provider of clinical laboratory testing and drug development services.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise UK market valuation (£3,144.9M in 2025) and verified forecast data (£5,468.4M by 2030) to support investment decisions, business planning, and competitive positioning in the high-growth UK biomarkers sector.
      • Segment-Specific Insights : Access detailed analysis of oncology, cardiovascular, and neurodegenerative biomarker segments specific to the UK market, enabling targeted product development and go-to-market strategies for your organization.
      • Regulatory & Reimbursement Landscape : Understand UK-specific regulatory pathways through MHRA, NHS reimbursement mechanisms, and clinical adoption barriers to accelerate product commercialization and market entry strategies.
      • Competitive Intelligence : Benchmark against UK market leaders, identify white-space opportunities, and assess competitive threats within the precision medicine ecosystem to inform strategic partnerships and M&A decisions.
      • Healthcare Provider Insights : Gain actionable intelligence on NHS trust adoption rates, private healthcare provider preferences, and clinical decision-making factors to optimize sales strategies and customer engagement in the UK market.

      Frequently asked questions

      What is the current size of the UK biomarkers market?

      The UK biomarkers market is valued at £3,144.9 million in 2025 and is projected to reach £5,468.4 million by 2030.

      What is the growth rate of the UK biomarkers market?

      The UK biomarkers market is growing at a compound annual growth rate (CAGR) of 11.7% from 2025 to 2030.

      Which disease segments drive the UK biomarkers market?

      The UK biomarkers market is primarily driven by oncology, cardiovascular disease, and neurodegenerative disease segments requiring precision diagnostics and treatment selection.

      How does the UK's NHS influence biomarker adoption?

      The UK's NHS integration of molecular testing and reimbursement policies accelerates clinical adoption and standardization of biomarker-based diagnostics across the healthcare system.

      What factors support biomarker market growth in the UK?

      The UK's advanced healthcare infrastructure, precision medicine initiatives, life sciences investment, and supportive regulatory environment drive biomarker innovation and commercialization.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.

      The following is a breakdown of the primary respondents:

      Biomarkers Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the biomarkers market was generated.
      • The revenues generated from their biomarker products have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined by each segment's revenue. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Biomarkers Market : Top-Down and Bottom-Up Approach

      Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.

      The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.

      Key Stakeholders

      • Academic & Research Institutes
      • Biomarkers Assay & Reagent Manufacturers, Vendors, and Distributors
      • Start-ups, platform technology & service providers
      • Contract Research Organizations (CROs)
      • Diagnostic product providing companies
      • Market Research and Consulting Firms
      • Pharmaceutical and Biotechnology Companies
      • Regulatory Agencies
      • Venture Capitalists
      • Forensic Labs
      • Government organizations
      • Private Research Firms
      • Contract Development and Manufacturing Organizations (CDMOs)
      • Hospitals and Diagnostic Laboratories

      Report Objectives

      • To define, describe, and forecast the global biomarkers market by offering, type, research area, technology, disease indication, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biomarkers market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global biomarkers market and comprehensively analyze their product & service portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
      • To benchmark players within the biomarkers market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product & service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:

      Portfolio Assesment

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

      Regional Analysis

      • A further breakdown of the Rest of Asia Pacific biomarkers market into countries
      • A further breakdown of the Rest of Europe biomarkers market into countries
      • A further breakdown of the Rest of Latin America biomarkers market into countries

      Company Information

      • Detailed analysis and profiling of additional market players (up to three).

      Get the Full Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Biomarkers Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status